Global Sotrovimab Injection Market Outlook
Revenue, 2024
Forecast, 2034
CAGR, 2024 - 2034
The Sotrovirinab Injection is an effective antiviral medication known for its strong ability to combat various viral infections effectively and aiding in the rapid recovery and alleviation of symptoms, in individuals facing serious health conditions.
Market Key Insights
- The Sotrovimab Injection market is projected to grow from $1.9 billion in 2024 to $3.4 billion in 2034. This represents a CAGR of 5.8%, reflecting rising demand across COVID-19 Treatment, Outpatient Infusion Centers and Monoclonal Antibody Therapy.
- GSK Pharmaceuticals, Vir Biotechnology, Marketair Inc are among the leading players in this market, shaping its competitive landscape.
- U.S. and Germany are the top markets within the Sotrovimab Injection market and are expected to observe the growth CAGR of 3.8% to 5.6% between 2024 and 2030.
- Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 6.7% to 8.0%.
- Transition like Advanced Pharmacotherapy Boost is expected to add $200.0 million to the Sotrovimab Injection market growth by 2030
- The Sotrovimab Injection market is set to add $1.5 billion between 2024 and 2034, with manufacturer targeting Biotech & Research Institutes End-user Industries projected to gain a larger market share.
- With Rising demand due to covid-19, and Technological advancements in drug delivery systems, Sotrovimab Injection market to expand 76% between 2024 and 2034.
Opportunities in the Sotrovimab Injection
Utilizing cutting edge drug delivery methods could boost the effectiveness of Sotrovimab Injection with side effects paving the way for potential growth through innovations in nano tech delivery and improved injection designs, in healthcare.
Growth Opportunities in North America and Europe
North America Outlook
Europe Outlook
Market Dynamics and Supply Chain
Driver: Rising Demand Due to COVID-19, and Growing Focus on Personalized Medicine
Progress in improving the delivery of medication has also supported the expansion of the market for Sotrovimab Injection by making it more effective and efficient, in treating patients while ensuring outcomes.
Restraint: Regulatory Hurdles
Opportunity: Strategic Collaborations in Global Supply Chain and Exploring Untapped Markets
The full potential of Sotrovimbab Injection has not only been fully realized in developing regions such as Asia and South America where the number of cases is high; thus increasing the need for effective treatments, like Sotrovimbab Injection is anticipated.
Challenge: High Production Costs
Supply Chain Landscape
Lonza Group
Sigma-Aldrich
Regeneron Pharmaceuticals
Eli Lilly and Company
Vir Biotechnology
GSK
AmerisourceBergen
McKesson Corporation
Lonza Group
Sigma-Aldrich
Regeneron Pharmaceuticals
Eli Lilly and Company
Vir Biotechnology
GSK
AmerisourceBergen
McKesson Corporation
Applications of Sotrovimab Injection in COVID-19 Treatment, Outpatient Infusion Centers & Monoclonal Antibody Therapy
Recent Developments
Gilead Sciences conducted a pioneering research study on Sotrovimab Injections lasting effectiveness, in controlling viral load. p>.